Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.37 |
| ▸ | HTR3B | O95264 | 3/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19498194 | 0.86 | GAA (0.43) | HTR2AHTR2CALDH1A1CYP1A2KDM4E | |
| SCHEMBL17624444 | 0.81 | HTR2A (0.45) | HTR2AHTR2CHTR3AALDH1A1HTR3E | |
| SCHEMBL19498196 | 0.81 | CHRM3 (0.33) | HTR2AHTR2C | |
| SCHEMBL19498569 | 0.80 | HPGDS (0.34) | HTR2AHTR2C | |
| SCHEMBL19498195 | 0.78 | PDE10A (0.40) | — | |
| SCHEMBL19498168 | 0.75 | MAPT (0.41) | HTR3AHRH4MAPTPOLB | |
| SCHEMBL19498162 | 0.74 | CYP1A2 (0.32) | HTR2AHTR2CHTR3AHTR3EHTR3B | |
| SCHEMBL19498567 | 0.73 | ABHD6 (0.43) | HTR2AHTR2CHTR3AHTR3EHTR3B | |
| SCHEMBL16639804 | 0.73 | DRD2 (0.34) | — | |
| SCHEMBL19498186 | 0.70 | NCF1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | HTR2A 4298/4885HTR2C 4771/4885HTR3A 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.